RxDoctor Payments Data

James Rutter, MD

Internal Medicine · Grove, OKNPI 1649258369

Payments from drug & device makers

$644in general payments, 2019–2025

Across 39 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$83
  • Amgen$77
  • Corium, LLC$76
  • Sunovion Pharmaceuticals Inc.$43
  • Exact Sciences$42
  • Novo Nordisk$34
  • plus $289 from 13 others

What the payments were for

  • Food & beverage$63098%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$644 in reported general payments places this provider in the 60th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$1,182
Medicare patients
18
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban144$165,282
MounjaroTirzepatide106$152,029
OzempicSemaglutide100$146,392
TrulicityDulaglutide47$64,639
XareltoRivaroxaban47$50,114
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$43,916
JardianceEmpagliflozin35$39,820
JanuviaSitagliptin Phosphate26$35,356
Breo ElliptaFluticasone/Vilanterol55$25,215
RybelsusSemaglutide18$20,823
MyrbetriqMirabegron26$16,995
EntrestoSacubitril/Valsartan17$15,980
Repatha SureclickEvolocumab20$15,515
Tresiba Flextouch U-200Insulin Degludec19$14,669
Spiriva HandihalerTiotropium Bromide24$14,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$28$219,753174 claims
Novo NordiskOzempic, Rybelsus$34$167,215118 claims
PfizerEliquis$16$165,282144 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$16$73,329135 claims
Boehringer IngelheimJardiance, Tradjenta$27$46,92547 claims
NovartisEntresto$30$15,98017 claims
AstraZenecaSymbicort$15$14,00342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Grove

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →